| LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer T Boulding, RD McCuaig, A Tan, K Hardy, F Wu, J Dunn, M Kalimutho, ... Scientific reports 8 (1), 73, 2018 | 142 | 2018 |
| Pharmacokinetics in Drug Development: Advances and Applications, Volume 3 PL Bonate, DR Howard Springer Science & Business Media, 2011 | 81* | 2011 |
| Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a … D Miles, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 32 (10), 1245-1255, 2021 | 51 | 2021 |
| Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors D Mahalingam, JJ Nemunaitis, L Malik, J Sarantopoulos, S Weitman, ... Cancer chemotherapy and pharmacology 74, 1241-1250, 2014 | 49 | 2014 |
| Targeting nuclear LSD1 to reprogram cancer cells and reinvigorate exhausted T cells via a novel LSD1-EOMES switch WJ Tu, RD McCuaig, AHY Tan, K Hardy, N Seddiki, S Ali, JE Dahlstrom, ... Frontiers in Immunology 11, 1228, 2020 | 44 | 2020 |
| Role of immunotherapy in bladder cancer: past, present and future SR Butt, L Malik Cancer Chemotherapy and Pharmacology 81, 629-645, 2018 | 44 | 2018 |
| Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in … D Mahalingam, L Malik, M Beeram, J Rodon, K Sankhala, A Mita, ... Cancer chemotherapy and pharmacology 74, 77-84, 2014 | 33 | 2014 |
| Optimizing poly (ADP‐ribose) polymerase inhibition through combined epigenetic and immunotherapy T Prasanna, F Wu, KK Khanna, D Yip, L Malik, JE Dahlstrom, S Rao Cancer Science 109 (11), 3383-3392, 2018 | 31 | 2018 |
| Relationship of pharmacokinetics (PK), toxicity, and initial evidence of clinical activity with IMGN853, a folate receptor alpha (FRa) targeting antibody drug conjugate in … KN Moore, J Ponte, P LoRusso, MJ Birrer, TM Bauer, H Borghaei, ... Journal of Clinical Oncology 32 (15_suppl), 5571-5571, 2014 | 26 | 2014 |
| Eligibility criteria for phase I clinical trials: tight vs loose? L Malik, D Lu Cancer Chemotherapy and Pharmacology 83, 999-1002, 2019 | 21 | 2019 |
| Predicting success in regulatory approval from Phase I results L Malik, A Mejia, H Parsons, B Ehler, D Mahalingam, A Brenner, ... Cancer chemotherapy and pharmacology 74, 1099-1103, 2014 | 19 | 2014 |
| Nuclear-biased DUSP6 expression is associated with cancer spreading including brain metastasis in triple-negative breast cancer F Wu, RD McCuaig, CR Sutton, AHY Tan, Y Jeelall, EG Bean, J Dai, ... International journal of molecular sciences 20 (12), 3080, 2019 | 18 | 2019 |
| How well informed is the informed consent for cancer clinical trials? L Malik, J Kuo, D Yip, A Mejia Clinical Trials 11 (6), 686-688, 2014 | 18 | 2014 |
| First-in-human phase 1 dose-escalation study of AV-203, a monoclonal antibody against ERBB3, in patients with metastatic or advanced solid tumors. J Sarantopoulos, MS Gordon, RD Harvey, KK Sankhala, L Malik, ... Journal of Clinical Oncology 32 (15_suppl), 11113-11113, 2014 | 17 | 2014 |
| Increasing complexity in oncology phase I clinical trials L Malik, D Lu Investigational new drugs 37, 519-523, 2019 | 15 | 2019 |
| Advanced cancer patients’ understanding and perceptions of phase I clinical trials J Pawlowski, L Malik, D Mahalingam Cancer Investigation 33 (10), 490-495, 2015 | 12 | 2015 |
| Informed consent for phase I oncology trials: form, substance and signature L Malik, A Mejia Journal of Clinical Medicine Research 6 (3), 205, 2014 | 11 | 2014 |
| Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2+/HR+ metastatic breast cancer M Loft, SW Lok, R De Boer, L Malik, S Greenberg, B Yeo, A Anton, ... Breast Cancer Research and Treatment 198 (1), 67-74, 2023 | 9 | 2023 |
| Simple and effective bacterial-based intratumoral cancer immunotherapy CSE Carroll, ER Andrew, L Malik, KF Elliott, M Brennan, J Meyer, A Hintze, ... Journal for immunotherapy of cancer 9 (9), 2021 | 9 | 2021 |
| Selective Targeting of Protein Kinase C (PKC)-θ Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8+ T Cells in … J Dunn, RD McCuaig, AHY Tan, WJ Tu, F Wu, KM Wagstaff, A Zafar, S Ali, ... Cancers 14 (6), 1596, 2022 | 8 | 2022 |
